Forecast Period | 2025-2029 |
Market Size (2023) | USD 16.31 Billion |
CAGR (2024-2029) | 7.36% |
Fastest Growing Segment | BNP and NT-proBNP |
Largest Market | North America |
Market Size (2029) | USD 24.70 Billion |
Market Overview
Global Cardiac Biomarkers Market was valued at USD
16.31 Billion in 2023 and is anticipated to project steady growth in the
forecast period with a CAGR of 7.36% through 2029. The global cardiac
biomarkers market is experiencing dynamic growth, driven by advancements in
healthcare diagnostics, increasing prevalence of cardiovascular diseases
(CVDs), and the growing emphasis on early disease detection and personalized
medicine. Cardiac biomarkers, crucial indicators measured in blood or urine,
provide valuable insights into the heart's health status, aiding in diagnosis,
risk stratification, and treatment monitoring.
Cardiac biomarkers are proteins, enzymes, hormones,
or other molecules released into the bloodstream in response to cardiac stress,
injury, or dysfunction. These biomarkers serve as sensitive indicators of
myocardial damage, inflammation, ischemia, and other cardiovascular conditions.
Widely used biomarkers include troponin, B-type natriuretic peptide (BNP),
creatine kinase (CK-MB), and myoglobin, each offering unique diagnostic
capabilities depending on the clinical context.
CVDs, including coronary artery disease, heart
failure, and myocardial infarction, remain leading causes of morbidity and
mortality worldwide. The rising incidence of these conditions underscores the
critical need for effective diagnostic tools like cardiac biomarkers to
facilitate early intervention and improve patient outcomes.
Innovations in immunoassay and molecular
diagnostics have enhanced the sensitivity, specificity, and multiplexing
capabilities of cardiac biomarker tests. High-sensitivity assays enable the
detection of biomarkers at lower concentrations, improving diagnostic accuracy
and clinical utility. Increasing focus
on personalized healthcare drives the demand for biomarker-based diagnostics
that enable tailored treatment strategies based on individual patient profiles.
Biomarker panels aid in risk assessment, treatment selection, and therapeutic
monitoring, fostering a more targeted approach to cardiac care.
Despite significant growth prospects, the global
cardiac biomarkers market faces challenges such as stringent regulatory
requirements, reimbursement issues, and variability in biomarker expression
among patient populations. Addressing these challenges requires ongoing
investment in research and development, clinical validation studies, and
collaboration with regulatory authorities to ensure compliance and market
access.
Key Market Drivers
Increasing Incidence of Cardiovascular Diseases
Cardiovascular diseases encompass a range of
conditions affecting the heart and blood vessels, including coronary artery
disease, heart failure, stroke, and hypertension. The escalating prevalence of
cardiovascular diseases worldwide drives the demand for cardiac biomarkers as
essential tools for disease management and patient care. Biomarker testing aids
in early diagnosis, which is crucial for improving treatment outcomes and
reducing healthcare costs associated with advanced disease stages.
According to statistics released by the World
Health Organization in June 2021, Cardiovascular diseases (CVDs) stand as the
primary cause of death worldwide. In 2019, approximately 17.9 million
individuals succumbed to CVDs, accounting for 32% of global mortality. Of these
fatalities, 85% were attributed to heart attacks and strokes. The vast majority
of CVD-related deaths, more than three quarters, occur in low- and
middle-income countries. Among the 17 million premature deaths due to
noncommunicable diseases in 2019, 38% were linked to CVDs. Many cardiovascular
diseases are preventable through addressing behavioral and environmental risk
factors such as tobacco use, unhealthy diet, obesity, physical inactivity,
excessive alcohol consumption, and air pollution. Early detection of
cardiovascular disease is crucial to initiate timely management through
counseling and medication.
Technological advancements in assay development,
including high-sensitivity assays and point-of-care testing, enhance the
accuracy, sensitivity, and speed of biomarker detection. These innovations
enable clinicians to obtain rapid and reliable diagnostic results, facilitating
prompt clinical decision-making.
There is a growing emphasis on personalized
medicine approaches tailored to individual patient profiles. Cardiac biomarkers
provide valuable information for risk assessment, treatment selection, and
monitoring response to therapy, supporting personalized treatment strategies
and improving patient outcomes.
Rising Healthcare Expenditure
Healthcare expenditure refers to the total amount
of money spent on healthcare goods and services, including medical treatments,
diagnostic tests, pharmaceuticals, and hospital care. Globally, healthcare
spending has been on the rise, driven by factors such as population aging, the
burden of chronic diseases, technological advancements, and improving access to
healthcare services.
Cardiovascular diseases (CVDs) are among the
leading causes of mortality and morbidity worldwide. As healthcare expenditures
increase, there is a heightened focus on preventing, diagnosing, and managing
cardiovascular conditions effectively. Cardiovascular health initiatives and
disease management programs benefit from increased funding, enabling healthcare
providers to adopt advanced diagnostic tools and biomarker testing for early
detection and personalized treatment strategies.
Advancements in diagnostic technologies have
transformed cardiac biomarker testing, enhancing its accuracy, efficiency, and
clinical utility. High-sensitivity assays and point-of-care testing have
streamlined biomarker detection, enabling rapid results and informed clinical
decision-making. These technological innovations are supported by increased
healthcare spending, which drives research and development in biomarker
discovery, validation, and commercialization.
The growth in healthcare expenditure contributes to
the expansion of the global cardiac biomarkers market by expanding access to
advanced healthcare services and diagnostic tools. Developed economies with
robust healthcare infrastructures lead in adopting new biomarker technologies,
while emerging markets benefit from healthcare investments aimed at improving
healthcare access and quality. This global accessibility fosters market growth
by broadening the adoption of biomarker testing across diverse healthcare settings
and patient populations.
Regulatory agencies play a crucial role in ensuring
the safety, efficacy, and quality of cardiac biomarker tests. As healthcare
expenditure increases, regulatory frameworks evolve to establish standardized
guidelines for biomarker testing, ensuring consistency in diagnostic practices
and results interpretation. Compliance with regulatory standards enhances
market confidence and facilitates market entry for new biomarker technologies,
driving innovation and market competitiveness.
Download Free Sample Report
Key Market Challenges
Patient Awareness and Compliance
Patient awareness and compliance play pivotal roles
in the effective utilization of cardiac biomarkers, yet they present
significant challenges in the global healthcare landscape. As advancements in
medical diagnostics continue to evolve, understanding and addressing these
challenges are crucial for maximizing the clinical utility and impact of
cardiac biomarkers in managing cardiovascular diseases.
Patient awareness regarding cardiac biomarkers
encompasses understanding their role in disease detection, monitoring, and
treatment decision-making. Many patients may not be familiar with biomarkers
such as troponin, B-type natriuretic peptide (BNP), or C-reactive protein
(CRP), which are crucial indicators of heart health. Awareness gaps can lead to
delayed testing, misinterpretation of symptoms, and suboptimal disease
management strategies.
Educational initiatives are essential to bridge
these gaps, empowering patients to recognize the significance of biomarker
testing in cardiovascular health. Healthcare providers play a pivotal role in
patient education, explaining the relevance of biomarkers in assessing cardiac
risk, diagnosing conditions like myocardial infarction or heart failure, and
guiding treatment interventions.
Patient compliance with biomarker testing
recommendations is influenced by various factors, including perceived
necessity, convenience, cost, and emotional factors. For instance, asymptomatic
individuals or those with mild symptoms may underestimate the urgency of
biomarker testing, potentially delaying diagnosis and treatment initiation.
Moreover, logistical challenges such as scheduling appointments, accessing
testing facilities, and financial considerations can deter patients from
undergoing timely biomarker assessments.
The lack of patient awareness and non-compliance
with biomarker testing recommendations can compromise diagnostic efficacy and
treatment outcomes in cardiovascular care. Delayed or missed diagnoses may lead
to progression of cardiovascular diseases, increased healthcare costs, and
poorer patient outcomes. Conversely, early detection facilitated by biomarker
testing enables prompt intervention and personalized treatment strategies,
significantly improving prognosis and quality of life.
Healthcare providers should implement comprehensive
educational programs to enhance patient understanding of cardiac biomarkers,
their clinical significance, and the benefits of early diagnosis. Clear
communication of test results and their implications is crucial for fostering
patient engagement.
Incorporating biomarker testing into integrated
care pathways promotes standardized protocols for cardiovascular disease
management. Seamless coordination between primary care providers, specialists,
and diagnostic laboratories facilitates timely testing and treatment
initiation.
Tailoring communication strategies to individual
patient preferences and health literacy levels enhances comprehension and promotes
informed decision-making regarding biomarker testing. Engaging patients as
partners in their healthcare journey fosters a collaborative approach to
disease management.
Key Market Trends
Expansion of Point-of-Care Testing
Cardiac biomarkers play a crucial role in the early
detection, diagnosis, and monitoring of cardiovascular conditions, such as
myocardial infarction (heart attack) and heart failure. Traditionally,
biomarker testing required samples to be sent to centralized laboratories,
resulting in delays in diagnosis and treatment initiation. The expansion of
POCT addresses these challenges by bringing diagnostic capabilities closer to
the patient, often within clinical settings like emergency departments,
ambulatory care centers, and physician offices.
The adoption of POCT for cardiac biomarkers offers
several strategic advantages. It enables
healthcare providers to obtain test results rapidly, typically within minutes,
facilitating prompt decision-making and timely interventions. This immediacy is
critical in emergency situations where every minute counts in determining the
appropriate course of treatment.
In February 2019, Government Medical College,
Thiruvananthapuram, acquired a state-of-the-art Point of Care (POC) system
designed to facilitate early identification of suspected acute myocardial
infarction (heart attack) using blood tests. The newly installed POC device,
cobas h 232, is now operational at the HDS lab at MCH. It enables rapid
detection and diagnosis of heart attacks by assessing cardiac biomarkers
including Troponin T, NT-proBNP, D-dimer, CK-MB, and Myoglobin in blood,
providing results within 14 minutes.
POCT reduces the logistical complexities associated
with sample transportation and processing times, thereby streamlining workflow
efficiencies within healthcare facilities. This streamlined process not only
enhances patient care but also contributes to cost savings by minimizing
unnecessary hospital admissions and reducing overall healthcare expenditures.
Technological advancements have been pivotal in
driving the expansion of POCT for cardiac biomarkers. Innovations in assay
sensitivity and specificity have led to the development of highly accurate and
reliable testing platforms that can deliver precise results even at the point
of care. These advancements include the miniaturization of testing devices,
integration of automated processes, and improvements in data connectivity for
seamless result reporting and integration into electronic health records
(EHRs).
The global market for cardiac biomarkers is poised
for continued growth, fueled by the increasing prevalence of cardiovascular
diseases worldwide and the ongoing shift towards personalized medicine.
Regulatory support and guidelines endorsing the use of biomarkers in clinical
practice further bolster market expansion. Strategic collaborations between
healthcare providers, diagnostic companies, and technology developers are also
expected to drive innovation and market penetration of POCT solutions.
Segmental Insights
Type Insights
Based on Type, BNP and NT-proBNP have emerged as
the fastest growing segment in the Global Cardiac Biomarkers Market in 2023. BNP
and NT-proBNP are peptides secreted by the heart in response to increased
cardiac wall stress, particularly in conditions like heart failure. Elevated
levels of these biomarkers in the blood indicate myocardial strain and are
indicative of heart failure severity. They are instrumental in diagnosing heart
failure, distinguishing it from other causes of dyspnea (difficulty breathing),
and guiding treatment decisions.
BNP and NT-proBNP are used for risk stratification
and prognosis assessment in patients with acute coronary syndromes and chronic
heart conditions. Their ability to predict adverse cardiovascular events, such
as myocardial infarction and cardiovascular mortality, enhances their clinical
utility and adoption in routine practice.
Advancements in assay technologies have improved
the sensitivity, specificity, and reliability of BNP and NT-proBNP tests,
making them more accessible and cost-effective for healthcare providers.
Point-of-care testing and high-sensitivity assays enable rapid and accurate
measurement of these biomarkers, facilitating timely clinical decision-making
and patient management.
Application Insights
Based on Application, Acute Coronary Syndrome have
emerged as the dominating segment in the Global Cardiac Biomarkers Market
during the forecast period. ACS encompasses a spectrum of conditions ranging
from unstable angina to myocardial infarction (heart attack), all of which pose
substantial risks to cardiovascular health. Globally, ACS is a leading cause of
morbidity and mortality, necessitating urgent medical intervention to prevent
irreversible damage to the heart muscle. The prevalence of ACS continues to
rise due to aging populations, sedentary lifestyles, and increasing incidence
of risk factors such as hypertension, diabetes, and obesity.
Diagnosing ACS promptly is crucial for initiating
timely treatments that can mitigate cardiac damage and improve patient
outcomes. Cardiac biomarkers play a pivotal role in the diagnostic pathway by
providing objective measurements of myocardial injury or stress. Biomarkers
such as troponin, CK-MB (creatine kinase-MB), and B-type natriuretic peptide
(BNP) are widely utilized to assess cardiac damage, risk stratify patients, and
guide clinical decision-making in ACS management.
Advancements in biomarker testing technologies,
particularly high-sensitivity assays, have revolutionized ACS diagnosis by
enhancing the sensitivity and specificity of biomarker detection.
High-sensitivity troponin assays, for example, can detect minute elevations in
troponin levels, enabling earlier identification of myocardial injury and more
accurate risk assessment for adverse cardiac events. These technological
innovations support faster triaging of patients in emergency departments and
facilitate personalized treatment strategies tailored to individual patient
needs.
ACS exerts a significant economic burden on healthcare
systems worldwide due to the high costs associated with hospitalization,
emergency care, and long-term management of cardiovascular complications. The
adoption of effective biomarker testing protocols in ACS diagnosis helps
optimize resource utilization, improve patient flow, and reduce healthcare
costs by minimizing unnecessary admissions and expediently addressing critical
cardiac conditions.
Download Free Sample Report
Regional Insights
Based on Region, North America have emerged as the dominating
region in the Global Cardiac Biomarkers Market in 2023. North America benefits
from a robust healthcare infrastructure and extensive research capabilities,
particularly in the field of cardiovascular medicine. The region is home to
renowned medical institutions, research universities, and biotechnology companies
that drive continuous innovation in biomarker discovery, validation, and
clinical application. These institutions leverage state-of-the-art technologies
and collaborative research networks to accelerate the development and
commercialization of novel cardiac biomarkers.
North America has historically been an early
adopter of technological innovations in healthcare, including cardiac biomarker
assays and diagnostic platforms. The region's healthcare providers and
laboratories embrace cutting-edge technologies such as high-sensitivity assays,
point-of-care testing devices, and digital health solutions that enhance the
accuracy, efficiency, and accessibility of biomarker testing. This proactive
approach positions North America at the forefront of cardiovascular diagnostics
globally.
Collaborative partnerships between academia,
industry, and government entities in North America foster synergies in
biomarker research and development. These partnerships facilitate
interdisciplinary collaborations, clinical trials, and regulatory advancements,
accelerating the translation of biomarker discoveries from bench to bedside.
Strategic alliances with global pharmaceutical companies and diagnostic
manufacturers further amplify North America's capabilities in commercializing
innovative biomarker-based diagnostics.
North America benefits from a well-established
regulatory framework and clear reimbursement policies that support the adoption
and commercialization of cardiac biomarkers. Regulatory agencies such as the
FDA (Food and Drug Administration) in the United States ensure rigorous
evaluation of biomarker assays for safety, efficacy, and clinical utility.
Clear reimbursement pathways through public and private healthcare systems
incentivize investment in biomarker development and facilitate market access
for innovative diagnostic products.
North America's leadership in the global cardiac
biomarkers market extends beyond domestic consumption to influence
international trends and standards. The region serves as a pivotal market for
global biomarker manufacturers and diagnostic companies, setting benchmarks for
product innovation, quality assurance, and regulatory compliance. Market
dynamics such as mergers, acquisitions, and strategic investments further
consolidate North America's position as a hub of biomarker development and
commercialization.
Recent Development
- In March 2024, the U.S. Food and Drug
Administration approved a new indication for Wegovy (semaglutide) injection.
This approval allows Wegovy to be used to reduce the risk of cardiovascular
death, heart attack, and stroke in adults diagnosed with cardiovascular disease
and either obesity or overweight. It is recommended that Wegovy be used
alongside a reduced calorie diet and increased physical activity.
Cardiovascular disease encompasses a range of conditions affecting the heart
and blood vessels. Wegovy contains semaglutide, a glucagon-like peptide-1
(GLP-1) receptor agonist, and should therefore not be administered concurrently
with other semaglutide-containing products or other GLP-1 receptor agonists.
Key Market Players
- Abbott Laboratories Inc.
- QuidelOrtho
Corporation
- Siemens
Healthineers AG
- F.
Hoffmann-La Roche Ltd
- Danaher
Corporation
- Bio-Rad
Laboratories, Inc.
- Randox
Laboratories Ltd.
- Creative
Diagnostics
- Life
Diagnostics Inc.
- BIOMÉRIEUX
Inc.
By Type
|
By Application
|
By Region
|
- Troponin
- CK-MB
- Myoglobin
- BNP and
NT-proBNP
- Others
|
- Acute
Coronary Syndrome
- Myocardial
Infarction
- Congestive
Heart Failure
- Others
|
- North
America
- Europe
- Asia Pacific
- South
America
- Middle East
& Africa
|
Report Scope:
In this report, the Global Cardiac Biomarkers
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- Cardiac Biomarkers Market, By Type:
o Troponin
o CK-MB
o Myoglobin
o BNP and NT-proBNP
o Others
- Cardiac Biomarkers Market, By Application:
o Acute Coronary Syndrome
o Myocardial Infarction
o Congestive Heart Failure
o Others
- Cardiac Biomarkers Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Cardiac
Biomarkers Market.
Available Customizations:
Global Cardiac Biomarkers Market report with the
given market data, Tech Sci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Cardiac Biomarkers Market is an upcoming
report to be released soon. If you wish an early delivery of this report or
want to confirm the date of release, please contact us at [email protected]